Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.
Valdivielso
José M
JM
Center for Glomerulonephritis, Emory University School of Medicine, Atlanta, GA, USA.
Montero
Angel
A
Munger
Karen A
KA
Badr
Kamal F
KF
D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D003921:Diabetes Mellitus, Experimental / Q000652:urine*; D003928:Diabetic Nephropathies / Q000517:prevention & control; D004231:Diuresis / Q000187:drug effects; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D011507:Proteinuria / Q000517:prevention & control*; D011804:Quinolines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D058927:5-Lipoxygenase-Activating Proteins; D001786:Blood Glucose; D002352:Carrier Proteins; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D011804:Quinolines; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; C063449:zileuton; D006918:Hydroxyurea